GLP-1 Medicines and Mental Health Changes

NCT07368855 | Completed

• 1 other identifier: E250185
• Study Type: interventional
• Target: 90
• Locations: 1 country
• Sites: 1

Brief Summary

Key question: Is the use of GLP-1 weight loss medicines - semaglutide and tirzepatide - associated with improvements in mental health and health-related quality of life? Key finding: Across six- months of GLP-1 treatment, participants reported statistically significant improvements in mental health, eating disorder symptoms, and health-related quality of life domains such as pain interference and sleep quality. Message for readers: Although GLP-1 medicines are prescribed primarily for weight loss and metabolic health benefits, growing evidence suggests that these medicines may also facilitate meaningful improvements in mental health and quality of life.

Conditions

Obesity; Depression; GLP-1

Keywords

Veterans, obesity, GLP-1, depression, mental health

Outcome Measures

Primary Outcomes (1)

• Beck Depression Inventory-2

  Changes in BDI-2 scores

  Six months

Study Arms (1)

GLP-1 medicine

OTHER

GLP-1 treatment

Drug: GLP-1

Interventions

GLP-1 DRUG

Wegovy or Zepbound

GLP-1 medicine

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Veterans receiving care at the VA San Diego Healthcare System

You may not qualify if:

• VASDHS Veterans not receiving GLP-1 medicines for obesity through the weight control clinic

Sponsors & Collaborators

• University of California, San Diego: lead

Study Sites (1)

VA San Diego Healthcare System

San Diego, California, 92161, United States

Location

MeSH Terms

Conditions

Obesity; Depression; Psychological Well-Being

Interventions

Glucagon-Like Peptide 1

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Behavioral Symptoms; Behavior; Personal Satisfaction

Intervention Hierarchy (Ancestors)

Glucagon-Like Peptides; Proglucagon; Gastrointestinal Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor in Residence/Staff Psychologist

Model Details: This study consisted of a retrospective observational study of participants receiving GLP-1 medicines for the treatment of obesity. We compared participants to their own baseline (i.e., status at the beginning of their GLP-1 treatment) to evaluate changes in psychiatric and eating disorder symptoms and health-related quality of life after six months of treatment. Participants consisted of US military veterans receiving care from a specialized weight management program in a large Veterans Affairs (VA) hospital in San Diego, California. To be eligible for GLP-1 treatment through the clinic, all veterans had previously completed lifestyle modification education and met national VA pharmacy criteria for having a diagnosis of obesity with one or more weight-related metabolic health conditions.

Study Record Dates

• First Submitted: January 20, 2026
• First Posted: January 27, 2026
• Study Start: May 1, 2024
• Primary Completion: July 1, 2025
• Study Completion: July 1, 2025
• Last Updated: January 27, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)